Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Prime Medicine, Inc. Common Stock
PRMEPrime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company has a strategic research collaboration and license agreement with bristol myers squibb to develop and commercialize multiple prime edited ex vivo t-cell therapies. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts. Address: 21 Erie Street, Cambridge, MA, United States, 02139
Analytics
Objectif de Cours de WallStreet
12.8 USDRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés PRME
Analyse des dividendes PRME
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes PRME
Valorisation des titres PRME
financières PRME
Résultats | 2019 | Dynamique |